PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
2.40%
Growth of 2.40% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
2.15%
Cost growth of 2.15% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
3.40%
Growth of 3.40% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
0.98%
Margin change of 0.98% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
-40.61%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
3.23%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 0.43%. Jim Chanos would check for waste.
2.32%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 0.91%. Jim Chanos would check for waste.
-5.26%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
269.38%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 21.26%. Jim Chanos would check for overinvestment.
39.53%
EBITDA growth exceeding 1.5x Medical - Pharmaceuticals median of 10.25%. Joel Greenblatt would investigate advantages.
36.26%
EBITDA margin growth exceeding 1.5x Medical - Pharmaceuticals median of 4.18%. Joel Greenblatt would investigate advantages.
4.04%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
1.61%
Margin change of 1.61% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-55.10%
Other expenses reduction while Medical - Pharmaceuticals median is 9.03%. Seth Klarman would investigate advantages.
-2.93%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-5.20%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
42.03%
Tax expense growth exceeding 1.5x Medical - Pharmaceuticals median of 0.96%. Jim Chanos would check for issues.
-15.54%
Net income decline while Medical - Pharmaceuticals median is -1.04%. Seth Klarman would investigate causes.
-17.52%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-15.54%
EPS decline while Medical - Pharmaceuticals median is -0.48%. Seth Klarman would investigate causes.
-15.54%
Diluted EPS decline while Medical - Pharmaceuticals median is -0.48%. Seth Klarman would investigate causes.
0.00%
Share count reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.16%. Joel Greenblatt would investigate strategy.
0.00%
Diluted share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.02%. Joel Greenblatt would investigate strategy.